Hemodialysis patients with a unique mineralizing defect unresponsive to  1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome

Cameron EC; Prior JC; Ballon HS

doi:10.1159/000403284

Therapeutics · Metabolic and Endocrine Agents

Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome

Cameron EC, Prior JC, Ballon HS

Contributions to Nephrology, 18, 162-171, 1980

DOI 10.1159/000403284 PMID 6986229

Abstract

5 patients are described who developed severe osteomalacia with spontaneous fractures after 2-4 years on dialysis. Phosphate control, vitamin D2 therapy and parathyroidectomy were ineffective. These individuals showed a hypercalcemic tendency but little histologic or radiographic evidence of osteitis fibrosa. After parathyroidectomy, the hypercalcemic tendency remained and bone biopsy revealed gross osteomalacia. A 6- to 12-month therapeutic trial with 1,25-dihydroxycholecalciferol (1,25[OH]2D3) in 3 did not arrest skeletal deterioration. 4 subsequently developed dialysis encephalopathy. These patients appear to have a unique mineralizing defect unresponsive to 1,25(OH)2D3. This "dialysis osteomalacic syndrome" may result from toxic substances associated with uremia or the hemodialysis regimen.

Topics

Therapeutics › Metabolic and Endocrine Agents › Corticosteroids · Bone Health › Hormones and Bone › Estrogen and Bone

Jerilynn C Prior

J Prior

PMID 6986229 6986229 DOI 10.1159/000403284 10.1159/000403284 Cameron et al. 1980, Cameron 1980

Keywords

Dihydroxycholecalciferols, Ergocalciferols, Hydroxycholecalciferols, Parathyroid Hormone, Alkaline Phosphatase, Calcium

Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome

Abstract

Topics

By this author

Energy intake and appetite in laboratory and free-living conditions may be consistent across menstrual cycle phases

MON-154 Breast areolar diameter in healthy menstruating women—a single cycle cross-sectional study of associations with body size and ovulatory characteristics

SAT-128 Prospective 1-year Menstrual CycleBreast Tenderness and Swelling Experiences—data from healthy regularly cycling women initially proven normally ovulatory on two consecutive cycles

SUN-109 Feasibility of Cyclic Progesterone and Spironolactone for PCOS-specific Health-Related Quality of Life—a six-month, Phase II, single arm, single center, open-label study

Related research

Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy

Dialysis encephalopathy and osteomalacic bone disease: a case-controlled study

Keywords